All news

Alnylam Pharmaceuticals (ALNY) Faces A Valuation Test After Fresh AMVUTTRA Data

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Alnylam Pharmaceuticals recently presented new clinical and real-world data for AMVUTTRA, but despite this and a solid Q3 update, the stock has fallen significantly. The market currently views ALNY as 53% undervalued with a fair value of $331.22, though potential risks like pricing pressure for AMVUTTRA could quickly change this outlook.

Read original source

ALNY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.